<p>Ginkgo Bioworks Holdings（纽约证券交易所代码：DNA）正在准备于 2026 年 2 月 26 日发布其季度财报。在公告之前，投资者应注意以下几点。</p>
<p>分析师预计 Ginkgo Bioworks Holdings 的 <strong>每股收益</strong>（EPS）为-$1.39。</p>
<p>Ginkgo Bioworks Holdings 的多头希望听到公司不仅超出该预期，还能提供积极的指引或下个季度的增长预测。</p>
<p>新投资者应注意，影响股票价格的往往不是盈利超预期或未达预期，而是指引（或预测）。</p>
<h3>过去的盈利表现</h3>
<p>上个季度，公司每股收益低于预期$0.21，导致次日股价下跌 20.8%。</p>
<p>以下是 Ginkgo Bioworks Holdings 的过去表现及其导致的价格变化：</p>
<table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">-1.24</td>
<td align="right">-1.44</td>
<td align="right">-1.23</td>
<td align="right">-1.30</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">-1.45</td>
<td align="right">-1.10</td>
<td align="right">-1.68</td>
<td align="right">-2.00</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">-20.80</td>
<td align="right">-8.69</td>
<td align="right">14.73</td>
<td align="right">-11.47</td>
</tr>
</tbody>
</table>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772042555_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="eps graph" width="700" height="500" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772042555_0.png"/></p>
<h3>Ginkgo Bioworks Holdings 股份表现</h3>
<p>截至 2 月 24 日，Ginkgo Bioworks Holdings 的股价为$8.86。在过去 52 周内，股价上涨了 7.99%。考虑到这些回报通常是积极的，长期股东在此次财报发布前可能持乐观态度。</p>
<h3>关于 Ginkgo Bioworks Holdings</h3>
<p>Ginkgo Bioworks Holdings Inc 是细胞编程的平台，提供灵活的端到端服务，解决来自食品和农业、制药到工业和特种化学品等多个市场的组织面临的挑战。公司将其运营重组为两个运营和报告部门：细胞工程：为各行业客户提供生物研发服务；生物安全：为政府和商业客户提供服务，以识别、监测、预防、减轻并最终保护人类免受生物威胁。收入的最大部分来自细胞工程部门。</p>
<h3>深入了解 Ginkgo Bioworks Holdings 的财务状况</h3>
<p><strong>市值视角：</strong> 公司的市值低于行业平均水平，表明其相较于同行规模较小。这种定位可能受到感知的增长潜力或运营规模等因素的影响。</p>
<p>** 收入挑战：**Ginkgo Bioworks Holdings 在过去 3 个月的收入增长面临困难。截至 2025 年 9 月 30 日，公司经历了约 <strong>-56.39%</strong> 的下降。这表明其收入出现了下降。与竞争对手相比，公司面临的增长率低于医疗保健行业的平均水平。</p>
<p>** 净利润率：**Ginkgo Bioworks Holdings 的净利润率令人印象深刻，超过行业平均水平。净利润率为 <strong>-207.93%</strong>，表明公司在盈利能力和成本管理方面表现强劲。</p>
<p>** 股本回报率（ROE）：**Ginkgo Bioworks Holdings 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-13.77%</strong>，公司可能在实现最佳财务回报方面遇到困难。</p>
<p><strong>资产回报率（ROA）：</strong> 公司的 ROA 低于行业基准，表明在有效利用资产方面可能存在困难。ROA 为 <strong>-6.67%</strong>，公司可能需要解决从资产中产生满意回报的挑战。</p>
<p>** 债务管理：**Ginkgo Bioworks Holdings 的债务与股本比率低于行业平均水平，为 <strong>0.76</strong>，反映出对债务融资的依赖较低，财务策略更为保守。</p>
<p>要跟踪 Ginkgo Bioworks Holdings 的所有财报发布，请访问我们网站上的财报日历。</p>
<p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>

动态生物技术与基因组 ETF - Invesco

医药突破 ETF - ALPS

标普生物技术 ETF - SPDR

纳斯达克生物科技指数 ETF - iShares Nasdaq

纽交所高增长板生物技术指数 ETF - First Trust

DNABW

2 倍做多纳斯达克生物技术 ETF - ProShares

IBBQ

生物科技 ETF - VanEck Vectors

<p>Ginkgo Bioworks Holdings（纽约证券交易所代码：DNA）将于 2026 年 2 月 26 日公布季度财报，分析师预测每股收益（EPS）为-1.39 美元。投资者对积极的指引充满期待，因为之前的每股收益未达预期导致股价下跌 20.8%。目前股价为 8.86 美元，过去一年上涨了 7.99%。公司面临收入挑战，增长率下降了 56.39%，但保持了强劲的净利润率，达到了-207.93%。Ginkgo 专注于细胞编程和生物安全，债务与股本比率为 0.76，属于保守水平</p>

<p>Ginkgo Bioworks Holdings (NYSE: DNA) is preparing to release its quarterly earnings on Thursday, 2026-02-26. Here's a brief overview of what investors should keep in mind before the announcement.</p>
<div class="lb-trans"><p>Ginkgo Bioworks Holdings（纽约证券交易所代码：DNA）正在准备于 2026 年 2 月 26 日发布其季度财报。在公告之前，投资者应注意以下几点。</p>
</div><p>Analysts expect Ginkgo Bioworks Holdings to report an <strong>earnings per share</strong> (EPS) of $-1.39.</p>
<div class="lb-trans"><p>分析师预计 Ginkgo Bioworks Holdings 的 <strong>每股收益</strong>（EPS）为-$1.39。</p>
</div><p>Ginkgo Bioworks Holdings bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.</p>
<div class="lb-trans"><p>Ginkgo Bioworks Holdings 的多头希望听到公司不仅超出该预期，还能提供积极的指引或下个季度的增长预测。</p>
</div><p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<div class="lb-trans"><p>新投资者应注意，影响股票价格的往往不是盈利超预期或未达预期，而是指引（或预测）。</p>
</div><h3>Past Earnings Performance</h3>
<div class="lb-trans"><h3>过去的盈利表现</h3>
</div><p>Last quarter the company missed EPS by $0.21, which was followed by a 20.8% drop in the share price the next day.</p>
<div class="lb-trans"><p>上个季度，公司每股收益低于预期$0.21，导致次日股价下跌 20.8%。</p>
</div><p>Here's a look at Ginkgo Bioworks Holdings's past performance and the resulting price change:</p>
<div class="lb-trans"><p>以下是 Ginkgo Bioworks Holdings 的过去表现及其导致的价格变化：</p>
</div><table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th align="right"><strong>Q3 2025</strong></th>
<th align="right"><strong>Q2 2025</strong></th>
<th align="right"><strong>Q1 2025</strong></th>
<th align="right"><strong>Q4 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td align="right">-1.24</td>
<td align="right">-1.44</td>
<td align="right">-1.23</td>
<td align="right">-1.30</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td align="right">-1.45</td>
<td align="right">-1.10</td>
<td align="right">-1.68</td>
<td align="right">-2.00</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td align="right">-20.80</td>
<td align="right">-8.69</td>
<td align="right">14.73</td>
<td align="right">-11.47</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th><strong>季度</strong></th>
<th align="right"><strong>2025 年第三季度</strong></th>
<th align="right"><strong>2025 年第二季度</strong></th>
<th align="right"><strong>2025 年第一季度</strong></th>
<th align="right"><strong>2024 年第四季度</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS 预估</strong></td>
<td align="right">-1.24</td>
<td align="right">-1.44</td>
<td align="right">-1.23</td>
<td align="right">-1.30</td>
</tr>
<tr>
<td><strong>EPS 实际</strong></td>
<td align="right">-1.45</td>
<td align="right">-1.10</td>
<td align="right">-1.68</td>
<td align="right">-2.00</td>
</tr>
<tr>
<td><strong>价格变化 %</strong></td>
<td align="right">-20.80</td>
<td align="right">-8.69</td>
<td align="right">14.73</td>
<td align="right">-11.47</td>
</tr>
</tbody>
</table>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2026/1772042555_0.png" alt="eps graph" original-src="https://www.benzinga.com/files/images/story/2026/1772042555_0.png"/></p>
<h3>Performance of Ginkgo Bioworks Holdings Shares</h3>
<div class="lb-trans"><h3>Ginkgo Bioworks Holdings 股份表现</h3>
</div><p>Shares of Ginkgo Bioworks Holdings were trading at $8.86 as of February 24. Over the last 52-week period, shares are up 7.99%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.</p>
<div class="lb-trans"><p>截至 2 月 24 日，Ginkgo Bioworks Holdings 的股价为$8.86。在过去 52 周内，股价上涨了 7.99%。考虑到这些回报通常是积极的，长期股东在此次财报发布前可能持乐观态度。</p>
</div><h3>About Ginkgo Bioworks Holdings</h3>
<div class="lb-trans"><h3>关于 Ginkgo Bioworks Holdings</h3>
</div><p>Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&amp;D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.</p>
<div class="lb-trans"><p>Ginkgo Bioworks Holdings Inc 是细胞编程的平台，提供灵活的端到端服务，解决来自食品和农业、制药到工业和特种化学品等多个市场的组织面临的挑战。公司将其运营重组为两个运营和报告部门：细胞工程：为各行业客户提供生物研发服务；生物安全：为政府和商业客户提供服务，以识别、监测、预防、减轻并最终保护人类免受生物威胁。收入的最大部分来自细胞工程部门。</p>
</div><h3>A Deep Dive into Ginkgo Bioworks Holdings's Financials</h3>
<div class="lb-trans"><h3>深入了解 Ginkgo Bioworks Holdings 的财务状况</h3>
</div><p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<div class="lb-trans"><p><strong>市值视角：</strong> 公司的市值低于行业平均水平，表明其相较于同行规模较小。这种定位可能受到感知的增长潜力或运营规模等因素的影响。</p>
</div><p><strong>Revenue Challenges:</strong> Ginkgo Bioworks Holdings's revenue growth over 3 months faced difficulties. As of 30 September, 2025, the company experienced a decline of approximately <strong>-56.39%</strong>. This indicates a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<div class="lb-trans"><p>** 收入挑战：**Ginkgo Bioworks Holdings 在过去 3 个月的收入增长面临困难。截至 2025 年 9 月 30 日，公司经历了约 <strong>-56.39%</strong> 的下降。这表明其收入出现了下降。与竞争对手相比，公司面临的增长率低于医疗保健行业的平均水平。</p>
</div><p><strong>Net Margin:</strong> Ginkgo Bioworks Holdings's net margin is impressive, surpassing industry averages. With a net margin of <strong>-207.93%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<div class="lb-trans"><p>** 净利润率：**Ginkgo Bioworks Holdings 的净利润率令人印象深刻，超过行业平均水平。净利润率为 <strong>-207.93%</strong>，表明公司在盈利能力和成本管理方面表现强劲。</p>
</div><p><strong>Return on Equity (ROE):</strong> Ginkgo Bioworks Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-13.77%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<div class="lb-trans"><p>** 股本回报率（ROE）：**Ginkgo Bioworks Holdings 的 ROE 低于行业平均水平，表明在有效利用股本方面可能面临挑战。ROE 为 <strong>-13.77%</strong>，公司可能在实现最佳财务回报方面遇到困难。</p>
</div><p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-6.67%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<div class="lb-trans"><p><strong>资产回报率（ROA）：</strong> 公司的 ROA 低于行业基准，表明在有效利用资产方面可能存在困难。ROA 为 <strong>-6.67%</strong>，公司可能需要解决从资产中产生满意回报的挑战。</p>
</div><p><strong>Debt Management:</strong> Ginkgo Bioworks Holdings's debt-to-equity ratio is below the industry average at <strong>0.76</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<div class="lb-trans"><p>** 债务管理：**Ginkgo Bioworks Holdings 的债务与股本比率低于行业平均水平，为 <strong>0.76</strong>，反映出对债务融资的依赖较低，财务策略更为保守。</p>
</div><p>To track all earnings releases for Ginkgo Bioworks Holdings visit their earnings calendar on our site.</p>
<div class="lb-trans"><p>要跟踪 Ginkgo Bioworks Holdings 的所有财报发布，请访问我们网站上的财报日历。</p>
</div><p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>
<div class="lb-trans"><p><em>本文由 Benzinga 的自动内容引擎生成，并由编辑审核。</em></p>
</div>

关于 Ginkgo Bioworks Holdings 即将发布的财报的深入分析